First quarter 2025 revenue
Revenue for the three months to 31 March 2025 rose by 4.8% on an organic basis, which equates to a 5.5% increase on a comparable number of days.
All businesses and regions contributed to revenue growth, with volume growth coming alongside positive price effects and case mix effects. The average occupancy rate of nursing homes was 90.4% in the first quarter of 2025, as opposed to 89.6% in the year-earlier period.
The disposal programme continued and more than 60% of the programme is now secured as opposed to 50% at 31 December 2024, for an expected total amount of €1 billion by the end of 2025.
Management confirmed its 2025 guidance:
- Organic revenue growth of around 5%
- EBITDA growth of between 6% and 9% pre-IFRS 16 and excluding disposals
- Wholeco leverage ratio1 of less than 5.5x
Wholeco leverage: leverage ratio adopted for the purposes of the amendment and extension of the syndicated loan announced on 17 February 2025. Wholeco leverage is calculated as follows: Net financial debt pre-IFRS 16 and IAS 17/consolidated EBITDA pre-IFRS 16 and IAS 17.
Ce premier trimestre vient confirmer la bonne dynamique opérationnelle des derniers semestres, dans les différentes activités et régions du Groupe, et l’engagement constant des collaborateurs. Dans notre principale activité de Maisons de retraite médicalisées, le taux d’occupation moyen s’élève à 90,4% sur l’ensemble du trimestre, en progression par rapport au premier trimestre 2024.
Nous avons par ailleurs continué de progresser dans l’exécution du programme de cessions engagé dans le cadre du plan de renforcement de la structure financière décidé en novembre 2023, en conduisant au cours de ce premier trimestre 6 opérations supplémentaires, portant sur une quinzaine d’établissements et réseaux de santé, situés en France, en Allemagne et en Italie, pour un montant d’environ 100 millions d’euros. Sur cette base, ce sont donc un peu plus de 60% de notre programme de cessions, qui ont été réalisés ou sécurisés. Nous poursuivrons à un rythme soutenu l’exécution de ce programme pour atteindre l’objectif de 1 milliard d’Euros d’ici fin 2025 dans les meilleures conditions de valorisation.
Sur ces bases, et fort de l’engagement de nos collaborateurs et de la dynamique de développement dans nos différents segments d’activité et géographies, nous confirmons nos objectifs opérationnels et financiers 2025.
Disclaimer
This document contains forward-looking statements that involve risks and uncertainties, including those included or incorporated by reference, con-cerning the Group’s future growth and profitability that could cause actual results to differ materially from those indicated in the forward-looking statements. These risks and uncertainties relate to factors that the Company cannot control or estimate precisely, such as future market conditions. The forward-looking statements made in this document constitute expectations for the future and should be regarded as such. Actual events or re-sults may differ from those described in this document due to a number of risks and uncertainties described in Chapter 2 of the 2024 Universal Regis-tration Document filed with the AMF on March 31, 2025 under registration number D. 25-0209, available on the Company's website, (www.clariane.com) and that of the AMF (www.amf-france.org). All forward-looking statements included in this document are valid only as of the date of this press release. Clariane S.E. undertakes no obligation and assumes no responsibility to update the information contained herein beyond the requirements of applicable regulations.
Readers are cautioned not to place undue reliance on these forward-looking statements. Neither Clariane nor any of its directors, officers, employees, agents, affiliates or advisors accepts any responsibility for the reasonableness of any assumptions or opinions expressed or for the likelihood of any projections, prospects or performance being achieved. Any liability for such information is expressly excluded. Nothing in this document is, or should be construed as, a promise or representation regarding the future. Furthermore, nothing contained in this document is intended to be or should be construed as a forecast of results. Clariane’s past performance should not be taken as a guide to future performance.
In this press release, and unless indicated otherwise, all changes are stated on a year-on-year basis (2025/2024), and at constant scope and exchange rates.
The main alternative performance measures (APMs), such as EBITDA, EBIT, net debt and financial leverage, are defined in the Universal Registration Document available on the company’s website at www.clariane.com.
